Breakthrough in blood cancer treatment: AIIMS researchers develop promising CAR T-cell ...
AIIMS researchers claim to have made significant progress in developing chimeric antigen receptor (CAR) T-cell therapy, ...
来自MSN19 分钟
Huge ADHD breakthrough reveals best treatment for condition after thousands take part in trial
New research on ADHD treatments in adults has found that medication is more effective than therapy in reducing symptoms in ...
Gilead gets FDA breakthrough therapy status for Trodelvy
Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...
Multiple Sclerosis News Today1 天
Tolebrutinib for SPMS granted FDA breakthrough therapy designation
Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...
Targeted Oncology20 小时
FDA Grants Breakthrough Status to Sacituzumab Govitecan in ES-SCLC
The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...
Targeted Oncology1 天
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...
Scientists Crack Cancer’s Hidden Defense With a Breakthrough Protein Discovery
Scientists have discovered a key protein that helps cancer cells avoid detection by the immune system during a type of ...
Monthly Prescribing Reference1 天
Tobevibart Plus Elebsiran Designated Breakthrough Therapy for Chronic Hepatitis Delta
The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.
Breakthrough gene therapy offers new hope to child with muscular dystrophy
Monroe Carell was a natural fit to offer the new therapy. Its multidisciplinary DMD Clinic, co-directed by Burnette, Soslow ...
Nasdaq4 天
SNY's Tolebrutinib Gets FDA Breakthrough Therapy Tag for nrSPMS
Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, tolebrutinib, for treating adults with non-relapsing secondary ...